肿瘤M2型丙酮酸激酶检测在良性、恶性胸腔积液诊断中的价值被引量：1

Value of tumor type M2 pyruvate kinase in differential diagnosis of pleural effusion

导出

摘要目的通过检测胸腔积液中肿瘤M2型丙酮酸激酶(M2-PK)水平,探讨肿瘤M2-PK对良性、恶性胸腔积液的鉴别诊断价值。方法收集胸腔积液患者120例,按照类型分为良性胸腔积液组和恶性胸腔积液组。采用ELISA法测定2组胸腔积液中肿瘤M2-PK的浓度。结果肿瘤M2-PK在恶性胸腔积液组浓度为(35.19±2.91)IU/mL,良性胸腔积液组为(11.38±1.02)IU/mL,2组比较有显著性差异(P<0.01)。肺癌患者M2-PK的表达水平在鳞癌、腺癌和小细胞癌中无显著性差异,Ⅲ、Ⅳ期患者血浆中M2-PK水平显著高于Ⅰ、Ⅱ期(P均<0.05)。肿瘤M2-PK诊断恶性胸腔积液的敏感性为88%,准确性为89%,高于CEA和CA199。结论检测胸腔积液中肿瘤M2-PK浓度对鉴别良、恶性胸腔积液有较大价值,值得在临床推广应用。 Objective It is to approach the value of tumor M2 - PK for the differential diagnosis of benign and malignant pleural effusion by detecting pleural effusion tumor M2 pyruvate kinase （ M2 - PK ） level. Methods 120 patients with pleural effusion were selected, including 60 cases of benign pleura1 effusion and 60 cases of malignant pleural effusion. The level of tumor M2 - PK in pleural effusion for all patients was determined by ELISA. Results The concentration of tumor M2 - PK was （35.19 ± 2.91 ） IU/mL in malignant pleural effusion and （11.38 ± 1.02） IU/mL in benign pleural effusion, there was signif- icant difference （ P 〈 0.01 ）. For the levels of M2 - PK, there were no significant differences between squamous cell carcinoma, adenocarcinoma and small cell carcinoma, but the levels in plasma of patients with grade III and 1V were significantly higher than which with grade I and II （ all P 〈 0.05 ）. For diagnosis of malignant pleural effusions by tumor M2 - PK, the sen- sitivity was 88% , accuracy 89% , and they were higher than that of CEA and CA199. Conclusion The detection of tumor M2 - PK has major value in differentiating benign from malignant pleural effusions, it is worth for clinical application.

作者刘澄英倪华邵荣沙江明

机构地区东南大学医学院附属江阴医院

出处《现代中西医结合杂志》 CAS 2013年第9期931-933,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine

关键词肿瘤M2型丙酮酸激酶胸腔积液肿瘤标志物肺肿瘤 tumor M2 pyruvate kinase pleural effusion tumor markers lung cancer

分类号 R73 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1Spoden GA,Mazurek S, Morandell D,et al. Isotype-specific inhibi- tors of the glycolytic key regulator pyruvate kinase subtype M2 mod- erately decelerate tumor cell proliferation [ J]. Int J Cancer,2008, 123(2) :312 -321.
2Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours [ J ]. Ernst Schering Found Symp Proc,2007 (4) :99 - 124.
3Oremek GM,Teigelkamp S, Kramer W, et al. The pyruvate kinase isoenzyme tumor M2 (Tu M2 -PK)as a tumor marker for renal car- cinoma[ J ]. Anticancer Res, 1999,19:2599 - 2601.
4Hugo F, Fischer G, Eigenbrodt E. Quantitative detection of tumor M2 - PK in serum and plasma [ J ]. Anticancer Res, 1999,19:2753 - 2757.
5Riantawan P, Sanqsayan P, Banqpattanasiri K, et al. Limited addi- tive value of pleural fluid earcinoemhryonic antigen level in malig- nantpleural effusion [ J ]. Respiration,2000,67:24 - 29.
6Seemann MD, Beinert T, Furst H, et al. An evaluation of the tumour markers, eareinoembryonie antigen ( CEA ) , eytokeratin marker ( CY- FRA 21 - I) and neuron-specific enolase (NSE) in the differentia- tion of malignant from benign solitary pulmonary lesions [ J ]. Lung Cancer, 1999,26 : 149 - 155.